Clinical Trials Browser

NIH × Pancreatic Neoplasms × Bevacizumab × Clear all

NCT00114179 2020-10-30

Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 2 Completed

82 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00101348 2014-06-11

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Phase 1/2 Completed

66 enrolled

CNSGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00305877 2014-05-21

Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

Phase 2 Completed

137 enrolled 8 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00091026 2014-05-15

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase 2 Completed

143 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00088894 2013-06-05

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 3 Completed

590 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00028834 2013-01-24

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

Phase 2 Completed

50 enrolled

Gastrointestinal

Pancreatic Neoplasms